Mammal Patents (Class 800/14)
-
Publication number: 20140201858Abstract: The invention relates to organisms and compositions comprising one or more stem cells or one or more embryos, wherein the one or more stem cells or one or more embryos comprise one or more of the following mutations: (i) a deletion mutation; (ii) a knockout mutation; and/or (iii) an addition of a heterologous nucleic acid sequence; wherein the one or more mutations of (i), (ii), and/or (iii) are site-specific mutations caused by a Xanthomonas TAL nuclease (XTN). The invention also relates to method of mutating an embryo, iPS cell, stem cell, or more particularly a spermatogonial stem cell by exposing the nucleic acid sequence contained within such embryos or cell with a Xanthomonas TAL nuclease.Type: ApplicationFiled: May 17, 2012Publication date: July 17, 2014Applicant: Transposagen Biopharmaceuticals, IncInventors: Eric M. Ostertag, John S. Crawford, J. Keith Joung
-
Publication number: 20140201856Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: September 27, 2013Publication date: July 17, 2014Applicant: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Anais Legent, Ian Kirby
-
Publication number: 20140201854Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: September 27, 2013Publication date: July 17, 2014Applicant: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Anais Legent, Ian Kirby
-
Publication number: 20140182005Abstract: The present invention provides sperm cell targeting ligands, including DNA-binding proteins, that bind target molecules on the surface of, accessible from the surface of, or inside mammalian sperm cells and methods for producing the sperm cell targeting ligands. The sperm cell targeting ligands are used to separate sperm cells based upon sperm cell qualities, such as whether the cells contain X chromosomes or Y chromosomes. The invention also provides methods of sperm cell purification using targeted radiofrequency absorption enhancers and transgenic animals with sex-skewed ejaculate.Type: ApplicationFiled: April 10, 2013Publication date: June 26, 2014Applicant: BIOCERN, INC.Inventor: Biocern, Inc.
-
Publication number: 20140165222Abstract: The potential use of these “SUMO receptors” to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.Type: ApplicationFiled: March 8, 2012Publication date: June 12, 2014Applicant: ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNEInventor: Manuel Salvador Rodriguez Medina
-
Publication number: 20140150125Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: October 17, 2013Publication date: May 29, 2014Applicant: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Anais Legent, Ian Kirby
-
Patent number: 8722964Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.Type: GrantFiled: April 23, 2010Date of Patent: May 13, 2014Assignee: Transposagen Biopharmaceuticals, Inc.Inventors: Eric M. Ostertag, John Stuart Crawford
-
Publication number: 20140123330Abstract: A genetically modified livestock animal comprising a genome that comprises inactivation of a neuroendocrine gene selective for sexual maturation, with the inactivation of the gene preventing the animal from becoming sexually mature. Methods of using, and processes of making, the animals are taught.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Inventors: Daniel F. Carlson, Scott C. Fahrenkrug, Xavier Lauth
-
Patent number: 8704037Abstract: The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential.Type: GrantFiled: December 21, 2011Date of Patent: April 22, 2014Assignee: Case Western Reserve UniversityInventors: Stephen M. Selkirk, Robert H. Miller
-
Patent number: 8703485Abstract: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.Type: GrantFiled: May 30, 2008Date of Patent: April 22, 2014Assignee: OMT, Inc.Inventor: Roland Buelow
-
Publication number: 20140109247Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicants: National Cancer Center, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Takumi TERATANI, Takahiro OCHIYA
-
Publication number: 20140075585Abstract: The present invention relates to CD82 polypeptides of the mammalian tetraspanin CD82 protein family for use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to CD82 knockout and transgenic animals and their cells, tissues and organs. The present invention furthermore relates to antibodies against a CD82 polypeptide, pharmaceutical compositions comprising at least one inhibitor of a CD82 polypeptide or comprising cells, tissues and organs of animals in which the CD82 level, expression and/or activity is modified, and their use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to methods of diagnosing xenograft recognition and/or rejection and methods for the prevention and/or treatment of xenograft recognition and/or rejection as well as methods of xenotransplantation.Type: ApplicationFiled: September 12, 2012Publication date: March 13, 2014Inventors: Futwan Al-Mohanna, Soad Saleh, Ranjit Parhar, Reem Al-Hejailan, Razan Bekheet, Kate Collison
-
Publication number: 20140075586Abstract: Non-human totipotent or pluripotent cells are provided comprising at a genomic locus a self-excisable, recombinase expression cassette flanked with recombination recognition sites, wherein a recombinase gene is operably linked to a promoter that is active in a post-meiotic spermatid stage when cytoplasmic bridging occurs between spermatids. Compositions and methods are provided for making cassette-deleted F1 non-human animals, wherein the methods comprise employing totipotent or pluripotent cells containing a self-excisable, recombinase expression cassette.Type: ApplicationFiled: November 13, 2013Publication date: March 13, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Guochun Gong, Ka-Man Venus Lai, David Frendewey, David M. Valenzuela
-
Publication number: 20140068796Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.Type: ApplicationFiled: October 18, 2013Publication date: March 6, 2014Applicant: CRYSTAL BIOSCIENCE, INC.Inventors: William Don Harriman, Robert Etches, Phil Leighton
-
Publication number: 20140059709Abstract: The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to uric acid. In a particular embodiment the invention relates to a mammalian cell useful in detecting and/or degrading a harmful excess of uric acid comprising (a) a vector comprising a genetic code for the uricase sensor-regulator HucR from Deinococcus radiodurans R1 fused to a transactivation domain or a transrepressor domain; and (b) a vector comprising the corresponding operator sequence hucO from Deinococcus radiodurans R1 specifically binding the bacterial uric acid sensor-regulator HucR, a promoter and a polynucleotide coding for an endogenous or exogenous protein, e.g. a protein interacting with uric acid.Type: ApplicationFiled: October 3, 2013Publication date: February 27, 2014Applicant: ETH ZURICHInventors: Christian KEMMER, Wilfried WEBER, Martin FUSSENEGGER
-
Patent number: 8658133Abstract: Methods and compositions relating to Alzheimer's disease are provided, including proteins that are differentially expressed in Alzheimer's disease as compared to the normal state. Further provided are methods, particularly experimental paradigms, for the identification of differential expressed proteins that are potential molecular targets for compounds to treat or prevent Alzheimer's disease. Also provided are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.Type: GrantFiled: August 26, 2005Date of Patent: February 25, 2014Assignee: Proteome Sciences plcInventors: Malcolm Ward, Vaksha Patel, Emma McGregor, Nicola Leeds, Helen Byers, James Campbell, Kit-Yi Leung, Jules Westbrook
-
Publication number: 20140053287Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.Type: ApplicationFiled: August 14, 2013Publication date: February 20, 2014Applicant: VERENIUM CORPORATIONInventors: David P. WEINER, Lishan ZHAO, Peter LUGINBUHL, Ellen BURKE, Toby H. RICHARDSON, Paula M. HICKS
-
Patent number: 8652842Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.Type: GrantFiled: February 27, 2013Date of Patent: February 18, 2014Assignee: Therapeutic Human Polyclonals, IncInventors: Josef Platzer, Roland Buelow, Wim van Schooten
-
Publication number: 20140041066Abstract: A genetically modified livestock animal comprising a genomic modification to an eIF4G gene. Cells, genes, and proteins encompassing a protease-resistant eIF4G protein or gene.Type: ApplicationFiled: March 15, 2013Publication date: February 6, 2014Inventors: Daniel F. Carlson, Scott C. Fahrenkrug
-
Publication number: 20140041067Abstract: The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.Type: ApplicationFiled: October 11, 2013Publication date: February 6, 2014Applicant: Kymab LimitedInventors: Allan Bradley, Glenn Friedrich, E-Chiang Lee, Mark Strivens, Nicholas England
-
Publication number: 20140033336Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: ApplicationFiled: October 4, 2013Publication date: January 30, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: ANDREW J. MURPHY, GEORGE D. YANCOPOULOS, MARGARET KAROW, LYNN MACDONALD, SEAN STEVENS
-
Patent number: 8633348Abstract: The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain an exogenous gene encoding a recombinant fusion protein, wherein the presence, and expression, of said recombinant fusion protein renders said genetically-modified non-human animal sterile. Tools for generating such sterile genetically-modified non-human animal as well as methods of use thereof are also provided.Type: GrantFiled: August 26, 2010Date of Patent: January 21, 2014Assignees: Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute for Biomedical Research, Universität ZürichInventors: Pawel Pelczar, Thorsten Buch, Antoine Peters
-
Publication number: 20140013457Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: ApplicationFiled: September 25, 2013Publication date: January 9, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens
-
Publication number: 20140013456Abstract: A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided.Type: ApplicationFiled: September 18, 2013Publication date: January 9, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Publication number: 20140004537Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF.Type: ApplicationFiled: May 22, 2013Publication date: January 2, 2014Inventors: Randolph J. Noelle, Li-Fan Lu, Sergio Quezada, David Gondek
-
Publication number: 20130345405Abstract: The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.Type: ApplicationFiled: March 15, 2013Publication date: December 26, 2013Applicant: Erasmus University Medical CenterInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
-
Publication number: 20130347134Abstract: The present invention provides, inter alia, transgenic non-human animals, such as transgenic mice. The animals contain in their genome a polynucleotide encoding a von Willebrand factor (VWF) polypeptide, which polypeptide forms a thrombus when in the presence of human platelets. Nucleic acid sequences and vectors for generating the transgenic non-human animals, and methods for using the transgenic non-human animals are provided as well. Chimeric VWF proteins are also provided.Type: ApplicationFiled: June 20, 2013Publication date: December 26, 2013Inventors: Thomas Diacovo, Jianchun Chen
-
Publication number: 20130347138Abstract: The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies, eg, comprising human variable region sequences. The invention provides for enhanced AID and/or AID homologue spectra, thereby providing for the increased diversity as a result of somatic hypermutation and/or class-switch recombination during in vivo antibody generation. The invention also provides methods of generating antibodies using such vertebrates, as well as the antibodies per se, therapeutic compositions thereof and uses.Type: ApplicationFiled: May 8, 2013Publication date: December 26, 2013Applicant: Kymab LimitedInventor: Kymab Limited
-
Publication number: 20130336954Abstract: Staphylococcus aureus is notorious for developing resistance to virtually all antibiotics to which it is exposed. Staphylococcal phage 2638A endolysin is a peptidoglycan hydrolase that is lytic for S. aureus when exposed externally, making it a new antimicrobial candidate. It shares a common protein organization with over 40 other staphylococcal peptidoglycan hydrolases: a CHAP endopeptidase domain, a mid-protein amidase 2 domain and a C-terminal SH3b cell wall binding domain. It is the first phage endolysin reported with a cryptic translational start site between the CHAP and amidase domains. Deletion analysis indicates that the amidase domain confers most of the lytic activity and requires the full SH3b domain for maximal activity. It is common for one domain to demonstrate dominant activity over another; however, the phage 2638A endolysin is the first to show high amidase domain activity dominant over the N-terminal CHAP domain, an important finding for targeting novel peptidoglycan bonds.Type: ApplicationFiled: June 13, 2012Publication date: December 19, 2013Inventors: David M. Donovan, Igor V. Abaev
-
Publication number: 20130340104Abstract: Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.Type: ApplicationFiled: March 12, 2013Publication date: December 19, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Andrew J. Murphy
-
Publication number: 20130333058Abstract: Pluripotent cells are derived and maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and an antagonist of an FGF receptor.Type: ApplicationFiled: April 5, 2013Publication date: December 12, 2013Applicant: The University Court of The University of EdinburghInventors: Qi-Long Ying, Austin Gerard Smith
-
Publication number: 20130330771Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: ApplicationFiled: March 14, 2013Publication date: December 12, 2013Applicant: Erasmus University Medical CenterInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Mariuns Johannes Van Haperen
-
Publication number: 20130326645Abstract: Disclosed herein are methods and compositions for homology-independent targeted insertion of donor molecules into the genome of a cell.Type: ApplicationFiled: May 7, 2013Publication date: December 5, 2013Applicants: Dow AgroSciences LLC, Sangamo BioSciences, Inc.Inventors: Gregory J. Cost, Fyodor Urnov, William M. Ainley, Joseph F. Petolino, Jayakumar Pon Samuel, Steven R. Webb, Lakshmi Sastry-Dent
-
Publication number: 20130326646Abstract: The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins.Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicants: The Trustees of the University of Pennsylvania, The Regents of the University of MichiganInventors: John K. Fink, Shirley Rainer, Robert D. Nicholls, Jinghua Chai
-
Patent number: 8598409Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: GrantFiled: August 24, 2007Date of Patent: December 3, 2013Assignee: Intrexon CorporationInventors: Marianna Zinovievna Kapitskaya, Subba Reddy Palli
-
Publication number: 20130318640Abstract: The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.Type: ApplicationFiled: December 10, 2012Publication date: November 28, 2013Applicants: Baxter International Inc., Baxter Healthcare SAInventors: Baxter Healthcare SA, Baxter International Inc.
-
Publication number: 20130312129Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.Type: ApplicationFiled: July 3, 2013Publication date: November 21, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: David FRENDEWEY, Guochun GONG, Ka-Man Venus LAI, David M. VALENZUELA
-
Publication number: 20130312128Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.Type: ApplicationFiled: July 3, 2013Publication date: November 21, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: David FRENDEWEY, Guochun GONG, Ka-Man Venus LAI, David M. VALENZUELA
-
Publication number: 20130312130Abstract: Provided are methods for producing a reprogrammed fibroblast or epithelial cell. The methods include growing a plurality of fibroblasts or epithelial cells in monolayer culture to confluency; and disrupting the monolayer culture to place at least a fraction of the plurality of fibroblasts or epithelial cells into suspension culture under conditions sufficient to form one or more embryoid body-like spheres, wherein the one or more embryoid body-like spheres comprise one or more reprogrammed fibroblasts or epithelial cells that express one or more markers not expressed prior to the disrupting step. Also provided are reprogrammed fibroblasts or epithelial cells produced by the disclosed methods, formulations that include reprogrammed fibroblasts or epithelial cells, methods for using the reprogrammed fibroblasts or epithelial cells, methods for producing chimeric non-human mammals that include one or more sphere-induced Pluripotent Cells (siPS), and chimeric non-human mammals produced thereby.Type: ApplicationFiled: September 23, 2011Publication date: November 21, 2013Applicant: UNIVERSITY OF LOUISVILLEInventors: Douglas Dean, Yongqing Liu
-
Publication number: 20130298268Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.Type: ApplicationFiled: July 16, 2013Publication date: November 7, 2013Inventor: JAMES WEST
-
Publication number: 20130283404Abstract: Provided herein are compositions and methods for the diagnosis, monitoring, treatment, and/or prevention of autoimmune disease (e.g., lupus) based on a causal connection with various epigenetic markers (e.g., chromosome demethylation, overexpression of lupus markers, nitration of PKC? in response to oxidative stress, etc.).Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Applicant: The Regents of the University of MichiganInventors: Bruce C. Richardson, Anura Hewagama, Gabriela Gorelik
-
Publication number: 20130276156Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.Type: ApplicationFiled: September 13, 2012Publication date: October 17, 2013Applicant: Intrexon CorporationInventors: Tarlochan Singh DHADIALLA, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, JR., Mohan Philip
-
Publication number: 20130273021Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: March 11, 2011Publication date: October 17, 2013Applicant: SYNAGEVA BIOPHARMA CORP.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20130263293Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: March 28, 2012Publication date: October 3, 2013Applicant: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
-
Publication number: 20130254910Abstract: The instant invention relates to the use of 24-hydroxylated vitamin D compounds as therapeutics in mammalian bone fracture repair. In addition, the instant invention relates to novel 24-hydroxylated vitamin D compound receptors which can be employed in the development of compounds capable of facilitating fracture repair in animals. The instant invention also relates to nucleic acids encoding such receptors as well as vectors, host cells, transgenic animals comprising such nucleic acids and screening assays employing such receptors.Type: ApplicationFiled: May 30, 2013Publication date: September 26, 2013Applicant: Shriners Hospital For ChildrenInventor: Rene St-Arnaud
-
Patent number: 8541646Abstract: A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.Type: GrantFiled: October 4, 2010Date of Patent: September 24, 2013Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in BiomedicineInventors: Sean Stevens, Andrew J. Murphy, Richard Flavell, Elizabeth Eynon, Jorge Galan, Tim Willinger, Markus Manz, Anthony Rongvaux, George D. Yancopoulos
-
Patent number: 8541645Abstract: Provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of the effects of environmental stimuli on the development and progression of pathological conditions. The environmental stimuli can include, but are not limited to, exposure to tobacco (e.g., cigarette, etc.) smoke. Exemplary pathological conditions include, but are not limited to, atherosclerosis, other cardiovascular disease (CVD), and the like. Also provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of pharmaceutical compounds, compositions, and/or formulations that can be used to prevent or treat a given pathological condition brought on by exposure to a given environmental condition.Type: GrantFiled: December 8, 2009Date of Patent: September 24, 2013Assignee: University of CalcuttaInventors: Alok Kumar Sil, Tanusree Ray, Palash Chandra Maity
-
Publication number: 20130247236Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
-
Publication number: 20130247234Abstract: A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Publication number: 20130243759Abstract: The present invention relates inter alia to fertile non-human vertebrates such as mice and rats useful for producing antibodies bearing human variable regions, in which endogenous antibody chain expression has been inactivated.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: KYMAB LTD.Inventors: Glenn A. Friedrich, E-Chiang Lee